Masato Chiba

4.8k citations

114 papers · 3.7k indexed · 1 hit paper · h-index 35

Oncology top 1%
Pharmacology top 0.1%
Molecular Biology top 10%
Pulmonary and Respiratory Medicine top 5%
Pediatrics, Perinatology and Child Health top 2%

Co-authors: Jiunn H. Lin Joy A. Nishime Yasuyuki Ishii Thomas A. Baillie Yoshihiro Shibata Tetsuya Mitsudomi Masayo Yamazaki Suresh K. Balani
Topics: Pharmacogenetics and Drug Metabolism (35 papers)Lung Cancer Treatments and Mutations (29 papers)Drug Transport and Resistance Mechanisms (26 papers)
Cited by: Pharmacology Oncology Virology
Journals: SHILAP Revista de lepidopterologíaHepatology Pharmacological Reviews
Partner nations: Japan United States Canada

In The Last Decade

Masato Chiba

109 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations T. Koga, Kenichi Suda et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Masato Chiba

Since Specialization

Citations

This map shows the geographic impact of Masato Chiba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masato Chiba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masato Chiba more than expected).

Fields of papers citing papers by Masato Chiba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masato Chiba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masato Chiba. The network helps show where Masato Chiba may publish in the future.

Co-authorship network of co-authors of Masato Chiba

This figure shows the co-authorship network connecting the top 25 collaborators of Masato Chiba. A scholar is included among the top collaborators of Masato Chiba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masato Chiba. Masato Chiba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical factors associated with high PD‐L1 expression in patients with early‐stage non‐small cell lung cancer 2024 ·Thoracic Cancer ·Shuta Ohara,Kenichi Suda,Akira Hamada,Masato Chiba,Masaoki Ito,Masaki Shimoji,Toshiki Takemoto,Junichi Soh,Yasuhiro Tsutani	1
2	Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion 2023 ·Journal of Thoracic Oncology ·Akira Hamada,Kenichi Suda,Masaya Nishino,Keiko Obata,(unknown),(unknown),Shota Fukuda,Toshio Fujino,Shuta Ohara,T. Koga,Masato Chiba,Masaki Shimoji,Masaoki Ito,Toshiki Takemoto,Junichi Soh,Yasuhiro Tsutani,Tetsuya Mitsudomi	9
3	Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer 2021 ·Lung Cancer ·Shuta Ohara,Kenichi Suda,Toshio Fujino,Akira Hamada,T. Koga,Masaya Nishino,Masato Chiba,Masaki Shimoji,Toshiki Takemoto,Junichi Soh,Tetsuya Mitsudomi	10
4	Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis 2019 ·SHILAP Revista de lepidopterología ·Shuta Ohara,Kenji Tomizawa,Shigeki Shimizu,Kenichi Suda,Toshio Fujino,Akira Hamada,T. Koga,Masaya Nishino,Yoshihisa Kobayashi,Katsuaki Sato,Masato Chiba,Masaki Shimoji,Toshiki Takemoto,Junichi Soh,Tetsuya Mitsudomi	0
5	Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro 2019 ·Journal of Thoracic Oncology ·Toshio Fujino,Yoshihisa Kobayashi,Kenichi Suda,T. Koga,Masaya Nishino,Shuta Ohara,Masato Chiba,Masaki Shimoji,Kenji Tomizawa,Toshiki Takemoto,Tetsuya Mitsudomi	114
6	P1.13-41 In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping 2018 ·Journal of Thoracic Oncology ·Toshio Fujino,Kenichi Suda,Yoshihisa Kobayashi,Masaya Nishino,T. Koga,Shuta Ohara,Masato Chiba,Masaki Shimoji,(unknown),Tetsuya Mitsudomi	1
7	Effect of repeated oral administration of chondroitin sulfate on neuropathic pain induced by partial sciatic nerve ligation in mice 2018 ·Journal of Pharmacological Sciences ·Wataru Nemoto,Kotaro Yamada,Osamu Nakagawasai,(unknown),Masato Chiba,(unknown),(unknown),Koichi Tan‐No	4
8	Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer 2017 ·Lung Cancer ·Kenji Tomizawa,Shigeki Shimizu,Shuta Ohara,Toshio Fujino,Masaya Nishino,(unknown),Yoshihisa Kobayashi,Katsuaki Sato,Masato Chiba,Masaki Shimoji,Kenichi Suda,Toshiki Takemoto,Tetsuya Mitsudomi	11
9	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A 2017 ·BMC Cancer ·Masato Chiba,Yosuke Togashi,(unknown),Yoshihisa Kobayashi,Yu Nakamura,Hidetoshi Hayashi,Masato Terashima,Marco A. De Velasco,Kazuko Sakai,Yoshihiko Fujita,Tetsuya Mitsudomi,Kazuto Nishio	29
10	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer 2016 ·Molecular Cancer Therapeutics ·Yoshihisa Kobayashi,Koichi Azuma,Hiroki Nagai,Young Hak Kim,Yosuke Togashi,(unknown),Masato Chiba,Masaki Shimoji,Katsuaki Sato,Kenji Tomizawa,Toshiki Takemoto,Kazuto Nishio,Tetsuya Mitsudomi	57
11	A CASE OF RESECTED OF AN OSSIFIED METASTATIC LUNG TUMOR SECONDARY TO COLON CANCER 2011 ·Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) ·(unknown),Satoshi Shiono,Masami Abiko,Masato Chiba,(unknown),Tôru Satô	0
12	Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs 2011 ·Molecular Pharmacology ·Jun‐ichi Eiki,Yasufumi Nagata,Mayumi Futamura,(unknown),Tomoharu Iino,T. Nishimura,Masato Chiba,Sumika Ohyama,(unknown),Kenji Fujii,Hideka Hosaka,(unknown),(unknown),Tomoyuki Ohe,Songnian Lin,Ronald B. Langdon,Joel P. Berger	25
13	Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development 2009 ·The AAPS Journal ·Masato Chiba,Yasuyuki Ishii,Yuichi Sugiyama	168
14	Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys 2003 ·Xenobiotica ·Lixia Jin,(unknown),Masato Chiba,Jiunn H. Lin	5
15	Prediction of Hepatic Clearance and Availability by Cryopreserved Human Hepatocytes: An Application of Serum Incubation Method 2002 ·Drug Metabolism and Disposition ·Yoshihiro Shibata,Hiroyuki Takahashi,Masato Chiba,Yasuyuki Ishii	138
16	P450 interaction with farnesyl-protein transferase inhibitors metabolic stability, inhibitory potency, and P450 binding spectra in human liver microsomes 1 1Abbreviations: FTI, farnesyl-protein transferase inhibitor; FTase, farnesyl-protein transferase; and LC-MS, liquid chromatography-mass spectrometry. 2001 ·Biochemical Pharmacology ·Masato Chiba,Cuyue Tang,William Neway,Theresa M. Williams,S. J. DESOLMS,(unknown),John Wai,Jiunn H. Lin	19
17	Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. 1996 ·Drug Metabolism and Disposition ·Jiunn H. Lin,Masato Chiba,(unknown),Joy A. Nishime,Kari Vastag	44
18	Uptake of sulfate conjugates by isolated rat hepatocytes. 1996 ·Drug Metabolism and Disposition ·(unknown),Dominic Man-Kit Lam,Masato Chiba,(unknown),(unknown),K. Sandy Pang	24
19	MECHANISM OF ALTERATIONS OF NON-LINEARITY IN HEPATIC FIRST-PASS METABOLISM OF PROPRANOLOL : ALTERATIONS IN THE RELATIVE ABUNDANCE OF CYTOCHROME P-450 ISOZYMES IN THE LIVER MICROSOMES IN RELATION TO THE ORGAN-LEVEL METABOLIC ACTIVITIES 1990 ·Journal of Pharmacobio-Dynamics ·Shoichi Fujita,(unknown),(unknown),Kazuyoshi Suzuki,Yasuhiro Masubuchi,Masato Chiba,Yoshihiko Funae,(unknown)	2
20	Pharmacokinetic Correlation Between in Vitro Hepatic Microsomal Enzyme Kinetics and in Vivo Metabolism of Imipramine and Desipramine in Rats 1990 ·Journal of Pharmaceutical Sciences ·Masato Chiba,(unknown),Tokuji Suzuki	28

About Masato Chiba

Masato Chiba is a scholar working on Pharmacology, Oncology and Virology, having authored 114 papers that have together received 3.7k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (35 papers), Lung Cancer Treatments and Mutations (29 papers) and Drug Transport and Resistance Mechanisms (26 papers). The work is most often cited by research in Pharmacology (1.2k citations), Oncology (1.7k citations) and Virology (190 citations). Masato Chiba has collaborated with scholars based in Japan, United States and Canada. Frequent co-authors include Jiunn H. Lin, Joy A. Nishime, Yasuyuki Ishii, Thomas A. Baillie, Yoshihiro Shibata, Tetsuya Mitsudomi, Masayo Yamazaki, Suresh K. Balani, J H Lin and Masaki Shimoji. Their work appears in journals such as SHILAP Revista de lepidopterología, Hepatology and Pharmacological Reviews.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact